The design of Benzimidazole derivatives to bind to GDP-bound K-RAS for targeted cancer therapy
Abstract
KRAS is a proto-oncogene that plays an important role in cell proliferation and division. It is found to be mutated in approximately 25% of cancer tumors. Several studies have tried to find ways to inhibit the KRAS protein, with modest success. This research aims to design molecules to bind to GDP-bound KRAS to predict how different molecules might bind to an inactivated version of the protein. We observed the binding affinity of various small molecules using UCSF Chimera and Autodock Vina and modified them to enhance their affinity to GDP-bound KRAS. We hypothesized that oxygen additions to the compound would increase hydrogen bonds, which in turn would increase the thermodynamic favorability of binding. We observed that molecules with favorable free-energy binding affinities tended to have more hydrogen bonds between the ligand and the protein, and they were mostly between oxygens in the ligand and various residues on the protein. Certain benzimidazole derivatives, such as Methiazole and Fenbendazole, have been found to inhibit growth of KRAS-mutant cells, so we tested several benzimidazole derivatives on GDP-bound KRAS in silico. Irbesartan had the most favorable binding affinity after modifications as compared to the other compounds docked on GDP-bound KRAS. The modified versions of Irbesartan can bind to GDP-bound KRAS better than the original Irbesartan.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.